Edition:
United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

25.97USD
26 Aug 2016
Change (% chg)

$-0.53 (-2.00%)
Prev Close
$26.50
Open
$26.30
Day's High
$26.70
Day's Low
$25.66
Volume
329,648
Avg. Vol
205,874
52-wk High
$35.79
52-wk Low
$20.05

Latest Key Developments (Source: Significant Developments)

Genomic Health says may sell up to 13.7 mln shares
Thursday, 11 Aug 2016 05:34pm EDT 

Genomic Health Inc : Says may sell up to an aggregate of 13.7 million shares of common stock - SEC filing .Shares being offered by selling stockholders, co will not receive any proceeds from the sale.  Full Article

Genomic Health files for mixed shelf of up to $350 mln - SEC filing
Thursday, 11 Aug 2016 04:15pm EDT 

Genomic Health Inc : Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage: [GHDX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genomic Health posts Q2 loss per share $0.18
Tuesday, 2 Aug 2016 04:05pm EDT 

Genomic Health Inc : Q2 loss per share $0.18 . Q2 revenue $82 million versus $70.6 million . Is raising low end of both revenue and test guidance for full-year ending December 31, 2016 . Maintaining net loss guidance between $12 and $18 million at mid-point of revenue guidance, excluding items for 2016 . FY2016 earnings per share view $-0.45, revenue view $330.3 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.18, revenue view $81.3 million -- Thomson Reuters I/B/E/S . Raising total revenue to between $325 and $335 million for 2016 .Sees 2016 basic net loss per share of between $0.37 and $0.55.  Full Article

Genomic Health Inc raises FY 2015 guidance
Tuesday, 4 Aug 2015 04:07pm EDT 

Genomic Health Inc:Expects FY 2015 revenue of $289 to $302 million (formerly $292 to $305 million).Expects FY 2015 Net loss between $19 and $26 million (formerly $17 and $24 million), or basic net loss per share of between $0.59 and $0.81.FY 2015 revenue of $294 million and net income of $(23) million - Thomson Reuters I/B/E/S.  Full Article

Genomic Health Inc presents positive proof-of-concept data for bladder cancer liquid biopsy test
Tuesday, 16 Jun 2015 08:00am EDT 

Genomic Health Inc:Says positive results from a liquid biopsy proof-of-concept study demonstrating its ability to more conveniently detect disease recurrence with a level of accuracy comparable to cystoscopy, an invasive procedure for surveillance of early-stage bladder cancer.These results support Genomic Health's development of a urine test that may offer physicians and patients a non-invasive alternative for physicians to monitor patients' bladder cancer.Early-stage bladder cancer is estimated to recur in 10 to 15 percent of patients in the first year and in more than half of patients over time.Currently, bladder cancer surveillance is repeated at frequent intervals via a cystoscopy, a procedure that inserts an instrument equipped with a camera and light to look at the inside of the bladder.  Full Article

Genomic Health Inc gives FY 2015 guidance in line with analysts' estimates
Tuesday, 10 Feb 2015 04:05pm EST 

Genomic Health Inc:Expects FY 2015 total revenue of $292 to $305 million.FY 2015 net loss between $17 and $24 million, or basic net loss per share of between $0.53 and $0.75.FY 2015 revenue of $311 mln, net income of $(17) mln, EPS of $(0.53) -Thomson Reuters I/B/E/S.  Full Article

Genomic Health Inc gives Q4 2014 revenue guidance in line with analysts' estimates; sees FY 2014 revenue guidance at low end of prior guidance - Conference Call
Tuesday, 4 Nov 2014 04:30pm EST 

Genomic Health Inc:Expects Q4 2014 revenue to be in the range of 7pct year-over-year.Expects FY 2014 total revenue at the low end of full-year guidance.Reported revenue of $68.82 million in Q4 2013.Reported revenue of $261.60 million in FY 2013.FY 2014 revenue of $282.22 million - Thomson Reuters I/B/E/S.Q4 2014 revenue of $73.56 million - Thomson Reuters I/B/E/S.  Full Article

Genomic Health Inc announces positive results from clinical validation study of oncotype DX as predictor of near- and long-term outcomes in racially diverse group of prostate cancer patients
Monday, 29 Sep 2014 08:00am EDT 

Genomic Health Inc:Says positive results from an independent clinical study of Oncotype DX prostate cancer test, conducted with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research supported by team of investigators with USU.This new large study reconfirmed the biopsy-based test's Genomic Prostate Score (GPS) as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen (PSA) following surgery (biochemical recurrence).In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer.Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men.  Full Article

BRIEF-Genomic Health files for mixed shelf of up to $350 mln - SEC filing

* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage: